Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction

Crinetics Pharmaceuticals, Inc.

Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).
Normalized testosterone in 8/13 females; 6 of 11 impacted participants resumed menses during the 12-week study.
Total adrenal volume consistently reduced across all dose cohorts; polycythemia resolved in 5 of 6 impacted participants.
No treatment-related severe or serious AEs; no dose reductions or discontinuations; most common AEs were headache (7/28) and fatigue (5/28).
Crinetics plans to initiate a global Phase 3 pivotal trial in adults and a Phase 2b/3 pediatric study in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.